Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
41 studies found for:    "Merkel cell carcinoma"
Show Display Options
Rank Status Study
1 Recruiting MLN0128 in Recurrent/Metastatic Merkel Cell Carcinoma
Condition: Merkel Cell Carcinoma
Intervention: Drug: MLN0128
2 Unknown  F16IL2 Plus Paclitaxel in Metastatic Merkel Cell Carcinoma
Condition: Merkel Cell Carcinoma
Interventions: Drug: Arm A: F16IL2 in combination with paclitaxel;   Drug: Arm B: Paclitaxel
3 Active, not recruiting A Proof-of-Concept Trial of GLA-SE in Patients With Merkel Cell Carcinoma
Condition: Merkel Cell Carcinoma
Intervention: Biological: GLA-SE
4 Recruiting Adjuvant Therapy of Completely Resected Merkel Cell Carcinoma With 3 mg/kg BW Ipilimumab (Yervoy®) Versus Observation
Condition: Merkel Cell Carcinoma
Intervention: Drug: Ipilimumab
5 Available Expanded Access to Avelumab for Treatment of Metastatic Merkel Cell Carcinoma (mMCC)
Condition: Metastatic Merkel Cell Carcinoma
Intervention: Drug: Avelumab
6 Withdrawn Study of the Drug Ipilimumab for Metastatic Merkel Cell Carcinoma
Condition: Merkel Cell Carcinoma
Intervention: Drug: Ipilimumab
7 Terminated Viral Oncoprotein Targeted Autologous T Cell Therapy for Merkel Cell Carcinoma
Conditions: Recurrent Merkel Cell Carcinoma;   Stage IV Merkel Cell Carcinoma
Interventions: Biological: Aldesleukin;   Other: Laboratory Biomarker Analysis;   Biological: MCPyV TAg-specific Polyclonal Autologous CD8-positive T Cells;   Radiation: Radiation Therapy;   Biological: Recombinant Interferon Beta
8 Completed IL-12 Gene and in Vivo Electroporation-Mediated Plasmid DNA Vaccine Therapy in Patients With Merkel Cell Cancer
Condition: Merkel Cell Carcinoma
Interventions: Biological: interleukin-12 gene;   Biological: electroporation-mediated plasmid DNA vaccine therapy
9 Completed A Phase I, Exploratory, Intra-patient Dose Escalation Study to Investigate the Preliminary Safety, Pharmacokinetics, and Anti-tumor Activity of Pasireotide (SOM230) s.c.Followed by Pasireotide LAR in Patients With Metastaticmelanoma or Metastatic Merkel Cell Carcinoma
Condition: Metastatic Melanoma and Merkel Cell Carcinoma
Interventions: Drug: Pasireotide sub-cutaneous formulation;   Drug: Pasireotide lon acting release formulation
10 Active, not recruiting Cabozantinib in Recurrent/Metastatic Merkel Cell Carcinoma
Conditions: Merkel Cell Carcinoma;   Skin Cancer
Intervention: Drug: Cabozantinib
11 Recruiting QUILT-3.009: Study of aNK Infusions in Combination With ALT-803 in Patients With Stage III (IIIB) or Stage (IV) Merkel Cell Carcinoma (MCC)
Conditions: Stage IIIB Merkel Cell Carcinoma;   Stage IV Merkel Cell Carcinoma
Intervention: Biological: aNK (NK-92)
12 Active, not recruiting Merkel Positron Emission Tomography (PET) Protocol
Condition: Merkel Cell Carcinoma
Interventions: Drug: Carboplatin;   Drug: Etoposide;   Radiation: Radiotherapy
13 Recruiting Avelumab in Subjects With Merkel Cell Carcinoma (JAVELIN Merkel 200)
Condition: Carcinoma, Merkel Cell
Intervention: Drug: Avelumab
14 Recruiting Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma
Conditions: Merkel Cell Carcinoma;   Skin Cancer
Interventions: Drug: Nivolumab;   Drug: Ipilimumab;   Radiation: Stereotactic Body Radiation Therapy (SBRT)
15 Recruiting Localized Radiation Therapy or Recombinant Interferon Beta and Avelumab With or Without Cellular Adoptive Immunotherapy in Treating Patients With Metastatic Merkel Cell Carcinoma
Conditions: Merkel Cell Polyomavirus Infection;   Stage IV Merkel Cell Carcinoma
Interventions: Drug: Avelumab;   Other: Laboratory Biomarker Analysis;   Biological: MCPyV TAg-specific Polyclonal Autologous CD8-positive T Cells;   Radiation: Radiation Therapy;   Biological: Recombinant Interferon Beta
16 Completed S9716: Combination Chemotherapy in Treating Patients With Merkel Cell Cancer
Condition: Neuroendocrine Carcinoma of the Skin
Interventions: Drug: CMF regimen;   Drug: cyclophosphamide;   Drug: fluorouracil;   Drug: methotrexate
17 Recruiting A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors
Conditions: Melanoma;   Merkel Cell Carcinoma;   Other Solid Tumors
Interventions: Drug: TALIMOGENE LAHERPAREPVEC (TVEC);   Radiation: Hypofractionated Radiotherapy
18 Recruiting Pembrolizumab in Treating Patients With Advanced Merkel Cell Cancer
Conditions: Recurrent Merkel Cell Carcinoma;   Stage IIIA Merkel Cell Carcinoma;   Stage IIIB Merkel Cell Carcinoma;   Stage IV Merkel Cell Carcinoma
Interventions: Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab
19 Recruiting Treatment of Unresecable and/or Metastatic Merkel Cell Carcinoma by Somatostatine Analogues
Condition: Carcinoma, Merkel Cell
Intervention: Drug: Lanreotide
20 Completed S0331: Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer
Conditions: Recurrent Neuroendocrine Carcinoma of the Skin;   Stage II Neuroendocrine Carcinoma of the Skin;   Stage III Neuroendocrine Carcinoma of the Skin
Interventions: Drug: imatinib mesylate;   Other: laboratory biomarker analysis

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.